JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng maintains an Overweight rating on ITeos Therapeutics (NASDAQ:ITOS) but lowers the price target from $27 to $24.
August 12, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Brian Cheng maintains an Overweight rating on ITeos Therapeutics but lowers the price target from $27 to $24.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100